The highly contagious Delta variant in India in early 2021 led to a swift surge in COVID cases and deaths throughout Southeast Asia. At the time of the Delta surge in India, less than five percent of India’s population had been vaccinated.

Solution and Impact

DFC financing is helping Indian vaccine manufacturer, Biological E Limited, expand production capacity for at least one billion additional COVID vaccine doses.

After initially focusing on production for distribution in India, Biological E has extended its focus to other developing countries where supply is most limited. The company is also continuing to expand its development and production of vaccines for a variety of infectious and childhood diseases. Additional production capacity supported by DFC financing will enable the company to begin producing a new oral polio vaccine. Biological E supplies vaccines to 100 countries around the world.